Equities Analysts Set Expectations for Abeona Therapeutics Inc’s Q3 2024 Earnings (NASDAQ:ABEO)

Abeona Therapeutics Inc (NASDAQ:ABEO) – Investment analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for shares of Abeona Therapeutics in a report released on Wednesday, July 3rd. HC Wainwright analyst R. Selvaraju expects that the biopharmaceutical company will post earnings per share of ($0.36) for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.81) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($2.05) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($1.18) EPS.

A number of other research firms also recently issued reports on ABEO. StockNews.com downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Stifel Nicolaus began coverage on Abeona Therapeutics in a research note on Thursday, May 30th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, Cantor Fitzgerald dropped their price target on Abeona Therapeutics from $28.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, May 16th.

Abeona Therapeutics Trading Up 4.2 %

Abeona Therapeutics stock opened at $5.00 on Monday. The firm has a market cap of $204.80 million, a price-to-earnings ratio of -1.56 and a beta of 1.59. The stock has a fifty day simple moving average of $4.38 and a two-hundred day simple moving average of $5.62. Abeona Therapeutics has a 12 month low of $2.83 and a 12 month high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06).

Institutional Trading of Abeona Therapeutics

Institutional investors have recently made changes to their positions in the business. Western Standard LLC lifted its stake in Abeona Therapeutics by 68.5% in the 1st quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company’s stock worth $9,871,000 after purchasing an additional 553,377 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Abeona Therapeutics during the 3rd quarter valued at approximately $648,000. Jump Financial LLC bought a new stake in Abeona Therapeutics in the 4th quarter worth approximately $199,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Abeona Therapeutics during the 1st quarter worth approximately $91,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Insider Activity at Abeona Therapeutics

In related news, Director Leila Alland bought 11,000 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were bought at an average cost of $4.71 per share, for a total transaction of $51,810.00. Following the completion of the transaction, the director now owns 82,857 shares of the company’s stock, valued at $390,256.47. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Leila Alland bought 11,000 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were bought at an average cost of $4.71 per share, for a total transaction of $51,810.00. Following the completion of the transaction, the director now owns 82,857 shares of the company’s stock, valued at $390,256.47. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Vishwas Seshadri bought 10,000 shares of the stock in a transaction that occurred on Thursday, April 25th. The shares were bought at an average price of $3.20 per share, for a total transaction of $32,000.00. Following the completion of the transaction, the chief executive officer now directly owns 538,260 shares of the company’s stock, valued at approximately $1,722,432. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 42,758 shares of company stock worth $154,047. Corporate insiders own 5.30% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.